Development and validation of an audit instrument: the Prostate Outcomes Questionnaire

Lamping,; Rowe, W.B.; Black,; Lessof,

doi:10.1046/j.1464-410x.1998.00670.x

Cited by 5 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The retest component was carried out with the recommended 18 14 day period following initial testing. The sample size of 55 for this aspect of the work is comparable with other similar studies, 26,27 and judged to be satisfactory. 18 Completion of questionnaires in the waiting room does not unduly overestimate satisfaction compared with completion outside of the practice.…”

Section: Discussionsupporting

confidence: 79%

The General Practice Assessment Survey (GPAS): tests of data quality and measurement properties

Ramsay

Campbell²,

Schroter³

et al. 2000

Family Practice

120

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 79%

The General Practice Assessment Survey (GPAS): tests of data quality and measurement properties

Ramsay

Campbell²,

Schroter³

et al. 2000

Family Practice

120

View full text Add to dashboard Cite

“…141 Guidelines for the development, testing and dissemination of health measures have also been produced. 142,143 The present authors [144][145][146][147][148][149][150][151][152][153] and others (see refs 79-81 for reviews) have used these methods extensively to develop and validate outcome measures across areas of clinical medicine.…”

Section: Evaluating the Psychometric Properties Of Health Outcome Meamentioning

confidence: 99%

Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology

Smith¹,

Lamping²,

Banerjee

et al. 2005

Health Technol Assess

520

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS, the public...

show abstract

“…Several BPH‐specific QoL scales have been published, e.g. the IPSS, the Danish Prostate Symptom Score (DAN‐PSS‐1), the International Continence Society ‘male’ questionnaire short‐form (ICSmale‐SF), and the Prostate Outcomes Questionnaire [6–10]. However, the translation difficulties among different cultures have not been fully addressed and no previous work has been reported in China.…”

Section: Introductionmentioning

confidence: 99%

Development and validation of a quality‐of‐life scale for Chinese patients with benign prostatic hyperplasia

Shi

Sun

Cai³

et al. 2004

BJU International

View full text Add to dashboard Cite

A 74-item QoL scale for BPH (prior test version; BPH-QLS), including five domains (disease, physical, social, psychological, satisfaction) was developed and had good reliability and validity. The test-retest correlation coefficient and Cronbach's a coefficient of the BPH-QLS were 0.892 and 0.966. Thirteen common factors were extracted according to the conceptual model. The correlations of the BPH-QLS with the Short Form-36, the International Prostate Symptom Score (IPSS), and IPSS QoL score, and a published BPH-specific QoL scale were 0.784, 0.493, 0.462 and 0.762, respectively. The BPH-QLS could be used to discriminate among patients with a different QoL. CONCLUSIONThe new scale is reliable, valid and sensitive, and we recommend using the BPH-QLS in Chinese and Chinese-born patients worldwide to assist in clinical practice. KEYWORDSquality of life, scale, benign prostatic hyperplasia, validity, reliability OBJECTIVETo develop and validate a quality of life (QoL) scale for Chinese patients with benign prostatic hyperplasia (BPH). PATIENTS AND METHODSAccording to the QoL definition of the World Health Organisation, we adhered to the rigorous guidelines of instrument development to form a pool of items, selected items and validated the scale, using data from 256 patients with BPH. INTRODUCTIONBPH is one of the most common conditions associated with ageing in men and has been reported at autopsy in ª 40% of men aged 50-60 and in up to 70% aged > 60 years. A study of BPH in the general population in the Netherlands showed that the prevalence of BPH was lowest among men aged 45-49 years (2.7%) and increased with age to a maximum at 80 years (24%) [1]. In China, with the proportion of elderly increasing and with life-style changes, the incidence of BPH has increased in recent years. In 1998 the incidence of BPH in China was reportedly similar to that in developed countries [2]. An investigation of 30 provinces showed that of all urology inpatients, BPH accounted for 16%. It has become one of the primary diseases in urology [3]. Both BPH and some of the treatments for it can compromise the patients' quality of life (QoL) [4]. The International Consensus on Urological Disease stated that 'for men with symptomatic BPH who have not developed serious complications, the primary goal of medical therapy is to relieve symptoms and improve quality of life. ' [5]. Therefore, measuring QoL can be indispensable to studies of the long-term effectiveness of BPH treatment strategies. Several BPH-specific QoL scales have been published, e.g. the IPSS, the Danish Prostate Symptom Score (DAN-PSS-1), the International Continence Society 'male' questionnaire short-form (ICSmale-SF), and the Prostate Outcomes Questionnaire [6][7][8][9][10]. However, the translation difficulties among different cultures have not been fully addressed and no previous work has been reported in China. The aim of the present study was to develop a QoL scale for Chinese patients with BPH, to assist in clinical practice. PATIENTS AND METHODSFrom July 2002 to Janua...

show abstract

Development and validation of an audit instrument: the Prostate Outcomes Questionnaire

Cited by 5 publications

References 28 publications

The General Practice Assessment Survey (GPAS): tests of data quality and measurement properties

The General Practice Assessment Survey (GPAS): tests of data quality and measurement properties

Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology

Development and validation of a quality‐of‐life scale for Chinese patients with benign prostatic hyperplasia

Contact Info

Product

Resources

About